Tale Of Two Sarcoma Drugs: ODAC Gives Nod To GSK’s Votrient, Thumbs Down On Merck/Ariad’s Taltorvic

FDA’s Oncologic Drugs Advisory Committee deems the three-month median progression-free survival benefit with GlaxoSmithKline’s pazopanib clinically meaningful and views accelerated approval as a means for acquiring more efficacy data, particularly on symptom benefit. In contrast, panel says smaller median PFS benefit seen with Merck and Ariad’s ridaforolimus, coupled with its toxicities, makes it inappropriate in the maintenance setting.